Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer

A compound of formula (I)

• wherein
• R1 is selected from H, CN, NO2, NCS, SCN, F, Cl, Br, I, and OCF3;
• R2 is H;
• R3 is selected from
• wherein
• R5 and R6 are each individually selected from H, acyl, and C1-6 alkyl;
• R7 is selected from H, halo, NO2, cyano, OH, alkoxy, mercapto, thioalkoxy, amino, C1-6 alkyl, C1-7 haloalkyl, heterocycloalkyl, and aryl;
• X is selected from —CH2—, —CH2CH2—, —O—, —OCH2—, —CH2O—, —NR8—, —CH2NR8—, and —NR8CH2—;
• wherein R8 is selected from H and C1-C6 alkyl;
• and
• q is 0 to 4;
• R4 is independently selected from H, halo, OH, CN, NO2, sulfonato, formyl, carboxy, mercapto, amido, amino, or a moiety selected from alkyl, alkenyl, alkynyl, aryl alkyl, aryl, heterocycloalkyl, heteroaryl, heteroaryl alkyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkoxy, aryloxy, thioalkoxy, acyl, acyloxy, alkoxycarbonyl, alkoxycarbonyloxy, alkylamino, and dialkylamino, and wherein each moiety is optionally further substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, aryl alkyl, aryl, heterocycloalkyl, heteroaryl, heteroaryl alkyl, hydroxyalkyl, haloalkyl, aminoalkyl, alkoxy, aryloxy, thioalkoxy, acyl, acyloxy, alkoxycarbonyl, alkoxycarbonyloxy, alkylamino, and dialkylamino;
• m is independently 0 to 5;
• n and o are independently 0 to 4;
• and
• p is 1;
• or a pharmaceutically acceptable salt thereof.